The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: CAR-T cell-based compositions. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.
CAR-T cell-based compositions are a key innovation area in immuno-oncology
Chimeric Antigen Receptor (CAR)-T cell therapy is a type of cancer immunotherapy that uses genetically engineered T cells for the detection and destruction of cancer cells. CAR-T cell therapy uses modified autologous T-cells to express a CAR specific for a tumor antigen, followed by ex vivo cell expansion and re-infusion back to the patient.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 230+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of CAR-T cell-based compositions.
Key players in CAR-T cell-based compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to CAR-T cell-based compositions
|Company||Total patents (2010 - 2022)||Premium intelligence on the world's largest companies|
|Immatics||2063||Unlock Company Profile|
|Bristol-Myers Squibb||564||Unlock Company Profile|
|Memorial Sloan Kettering Cancer Center||355||Unlock Company Profile|
|Cellectis||301||Unlock Company Profile|
|Gilead Sciences||237||Unlock Company Profile|
|Autolus||228||Unlock Company Profile|
|Fred Hutchinson Cancer Research Center||222||Unlock Company Profile|
|bluebird bio||212||Unlock Company Profile|
|City of Hope||194||Unlock Company Profile|
|ImmunityBio||169||Unlock Company Profile|
|Iovance Biotherapeutics||150||Unlock Company Profile|
|Immunovative Therapies||139||Unlock Company Profile|
|CARsgen Therapeutics||132||Unlock Company Profile|
|Miltenyi Biotec||122||Unlock Company Profile|
|CRISPR Therapeutics||121||Unlock Company Profile|
|Seattle Children's Hospital||120||Unlock Company Profile|
|Pfizer||102||Unlock Company Profile|
|BioNTech||89||Unlock Company Profile|
|Sangamo Therapeutics||89||Unlock Company Profile|
|Takeda Pharmaceutical||80||Unlock Company Profile|
|Precision Biosciences||76||Unlock Company Profile|
|ONK Therapeutics||75||Unlock Company Profile|
|Allogene Therapeutics||74||Unlock Company Profile|
|Innovative Cellular Therapeutics||72||Unlock Company Profile|
|Massachusetts General Hospital||72||Unlock Company Profile|
|PT Soho Global Health Tbk||71||Unlock Company Profile|
|Targovax||66||Unlock Company Profile|
|Io Therapeutics||61||Unlock Company Profile|
|Eureka Therapeutics||61||Unlock Company Profile|
|TCR2 Therapeutics||56||Unlock Company Profile|
|Amgen||55||Unlock Company Profile|
|F. Hoffmann-La Roche||54||Unlock Company Profile|
|Nanjing Legend Biotech||53||Unlock Company Profile|
|United States Of America||52||Unlock Company Profile|
|Mayo Clinic||50||Unlock Company Profile|
|Adicet Bio||50||Unlock Company Profile|
|Editas Medicine||50||Unlock Company Profile|
|American Gene Technologies International||50||Unlock Company Profile|
|OncoTherapy Science||50||Unlock Company Profile|
|Atara Biotherapeutics||47||Unlock Company Profile|
|AiCuris Anti-infective Cures||46||Unlock Company Profile|
|CytoImmune Therapeutics||45||Unlock Company Profile|
|Fate Therapeutics||43||Unlock Company Profile|
|Genscript Biotech||42||Unlock Company Profile|
|Tessa Therapeutics||41||Unlock Company Profile|
|Gracell Biotechnologies||40||Unlock Company Profile|
|Nkarta||39||Unlock Company Profile|
|CERo Therapeutics||39||Unlock Company Profile|
|Hadasit Bio-Holdings||39||Unlock Company Profile|
|Aleta Biotherapeutics||39||Unlock Company Profile|
Source: GlobalData Patent Analytics
Immatics is a leading patent filer of CAR-T cell-based compositions. Its ACTengine programs are based on the genetic engineering of a patient’s own, autologous T cells with novel TCRs designed to recognise the cancer target on the tumour. The company has several assets such as IMA203, IMA201 and IMA204. It is developing TCR-based immunotherapies with an emphasis on treating various solid tumours.
In terms of application diversity, Genscript Biotech is the top company, followed by Turnstone Biologics and GammaDelta Therapeutics. By means of geographic reach, Otsuka holds the top position, while Genscript Biotech and OncoTherapy Science are in second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Immuno-Oncology – Thematic Research.